CJC-1295 is a modified GHRH analog with a DAC (Drug Affinity Complex) modification that significantly extends its half-life compared to native GHRH
(P7, male, diabetes) Improvements in social and interpersonal relationships were described, often related to an improvement in the participants overall mood and social confidence
Safety Profile Across Patient Populations and Risk Factors Safety outcomes vary based on individual factors: baseline B12 status, kidney function, history of injection reactions, and concurrent medications
Sideeffects are mild and transientdrowsiness, brief headache, vivid dreams, or occasional injectionsite irritationwithout tolerance or dependence Potential side effects include injection site irritation, headache, vivid dreams, and hormonerelated effects
GLP-1: The trusted option with a proven track record for sustained weight loss, cardiovascular protection, and long-term health benefits
Overall, the majority of the individuals were women (80.5%), with a mean ( standard deviation) age of 5311 years